Publication:
Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: A Turkish oncology group study

Simple item page
dc.contributor.authorBAŞOĞLU TÜYLÜ, TUĞBA
dc.contributor.authorYUMUK, PERRAN FULDEN
dc.contributor.authorsBAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
dc.date.accessioned2023-05-29T06:57:30Z
dc.date.available2023-05-29T06:57:30Z
dc.date.issued2023-01-01
dc.description.abstractNeoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare the efficacy and toxicity profile of different chemotherapy regimens in our country. This retrospective multicentre study included locally advanced GC and GEJ cancer patients who received NACT between 2007 and 2021. Relation between CT regimens and pathological evaluation were analysed. A total of 794 patients from 45 oncology centers in Turkey were included. Median age at the time of diagnosis was 60 (range: 18-86). Most frequent NACT regimens used were FLOT (65.4%), DCF (17.4%) and ECF (8.1%), respectively. In the total study group, pathological complete remission (pCR) rate was 7.2%, R0 resection rate 86.4%, and D2 dissection rate was 66.8%. Rate of pCR and near-CR (24%), and R0 resection (84%) were numerically higher in FLOT arm (p > 0.05). Patients who received FLOT had also higher chemotherapy-related toxicity rate compared to patients who received other regimens (p > 0.05). Median follow-up time was 16 months (range: 1-154 months). Estimated median overall survival (OS) was 58.4months (95% CI: 35.2-85.7) and disease-free survival (DFS) was 50.7 months (95% CI: 25.4-75.9). The highest 3-year estimated OS rate was also shown in FLOT arm (68%). We still do not know which NACT regimen is the best choice for daily practice. Clinicians should tailor treatment regimens according to patients\" multifactorial status and comorbidities for to obtain best outcomes. Longer follow-up period needs to validate our results.
dc.identifier.citationBAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al., "Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study", JOURNAL OF CHEMOTHERAPY, cilt.35, sa.2, ss.142-149, 2023
dc.identifier.doi10.1080/1120009x.2022.2073159
dc.identifier.endpage149
dc.identifier.issn1120-009X
dc.identifier.issue2
dc.identifier.startpage142
dc.identifier.urihttps://www.tandfonline.com/doi/epdf/10.1080/1120009X.2022.2073159?needAccess=true&role=button
dc.identifier.urihttps://hdl.handle.net/11424/289678
dc.identifier.volume35
dc.language.isoeng
dc.relation.ispartofJOURNAL OF CHEMOTHERAPY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectPatoloji
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectBasic Pharmaceutics Sciences
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectBiochemistry
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectSurgery Medicine Sciences
dc.subjectPathology
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectNatural Sciences
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPATOLOJİ
dc.subjectBiyoloji ve Biyokimya
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectINFECTIOUS DISEASES
dc.subjectIMMUNOLOGY
dc.subjectLife Sciences (LIFE)
dc.subjectPATHOLOGY
dc.subjectBIOLOGY & BIOCHEMISTRY
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectGenel İmmünoloji ve Mikrobiyoloji
dc.subjectFarmakoloji
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectFarmakoloji, Toksikoloji ve Eczacılık (çeşitli)
dc.subjectHistoloji
dc.subjectPatoloji ve Adli Tıp
dc.subjectFarmakoloji (tıbbi)
dc.subjectBiyokimya (tıbbi)
dc.subjectİlaç Rehberleri
dc.subjectBulaşıcı hastalıklar
dc.subjectGeneral Immunology and Microbiology
dc.subjectPharmacology
dc.subjectImmunology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectHistology
dc.subjectPathology and Forensic Medicine
dc.subjectPharmacology (medical)
dc.subjectBiochemistry (medical)
dc.subjectPharmacy
dc.subjectDrug Guides
dc.subjectInfectious Diseases
dc.subjectGastric cancer
dc.subjectgastroesophageal junction cancer
dc.subjectneoadjuvant chemotherapy
dc.subjectFOLINIC ACID
dc.subjectPHASE-II
dc.subjectPERIOPERATIVE CHEMOTHERAPY
dc.subjectFLUOROURACIL
dc.subjectOXALIPLATIN
dc.subjectMULTICENTER
dc.subjectREGRESSION
dc.subjectCISPLATIN
dc.subjectDOCETAXEL
dc.subjectSURGERY
dc.titleReal life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: A Turkish oncology group study
dc.typearticle
dspace.entity.typePublication
local.avesis.id07be9860-a99f-4369-b0c2-4274fbb4a5c7
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationddaeb928-6e68-4414-bd70-00515b6656a6
relation.isAuthorOfPublication4e7b3d69-6d73-4c60-89e4-d6fddfddd2aa
relation.isAuthorOfPublication.latestForDiscoveryddaeb928-6e68-4414-bd70-00515b6656a6

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
6.pdf
Size:
2.08 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs